Passer au contenu principal
Centre intégré universitaire de santé
et de services sociaux de l'Est-de-l'Île-de-Montréal

Centre intégré universitaire de santé et de services sociaux de l'Est-de-l'Île-de-Montréal

Julie Bergeron, M.D.

Julie Bergeron

Hémato-oncologue, Professeure agrégée de clinique

L'équipe de l’IHOT

Chercheur-clinicien

Contact

Tél. : 514 252-3404

Tout en complétant sa formation médicale, Dre Julie Bergeron a obtenu un Master II de l’Université Denis Diderot Paris VII en biologie moléculaire et fonctionnelle des cellules sanguines. Ses intérêts de recherche se situent principalement en leucémie aigüe.

 

  • Cheffe du service des laboratoires d’hématologie, grappe OPTILAB CHUM 
  • Membre du Comité de priorisation clinique et recherche de l'IHOT
  • Membre du Comité d’optimisation clinique de l’IHOT
  • Membre du Comité de direction de l'IHOT
  • Entrée en poste à l’Hôpital Maisonneuve-Rosemont : 1998

 

Formation :

  • Fellowship en hématologie biologique orienté vers la biologie moléculaire des hémopathies malignes : Institut national de santé et de la recherche médicale, Paris (France), 2005-2007
  • Résidences en médecine interne, hématologie et oncologie médicale : Université de Montréal (Canada), 1998-2004
  • Doctorat en médecine : Université Laval, Québec (Canada), 1993-1998

Découvrez ses publications

  • Blinatumomab for MRD-Negative Acute Lymphoblastic Leukemia in Adults

    Mark R Litzow, Zhuoxin Sun, Ryan J Mattison, Elisabeth M Paietta, Kathryn G Roberts, Yanming Zhang, Janis Racevskis, Hillard M Lazarus, Jacob M Rowe, Daniel A Arber, Matthew J Wieduwilt, Michaela Liedtke , Julie Bergeron , Brent L Wood, Yaqi Zhao, Gang Wu, Ti-Cheng Chang, Wenchao Zhang, Keith W Pratz, Shira N Dinner, Noelle Frey, Steven D Gore, Bhavana Bhatnagar, Ehab L Atallah, Geoffrey L Uy, Deepa Jeyakumar , Tara L Lin, Cheryl L Willman, Daniel J DeAngelo, Shejal B Patel, Michelle A Elliott, Anjali S Advani, Dimitrios Tzachanis, Pankit Vachhani, Rupali R Bhave, Elad Sharon , Richard F Little, Harry P Erba, Richard M Stone, Selina M Luger, Charles G Mullighan, Martin S Tallman
    DOI 10.1056/NEJMoa2312948 PMID 39047240
    Consulter

  • The Clinical Utility of FLT3 Mutation Testing in Acute Leukemia: A Canadian Consensus

    Julie Bergeron , Jose-Mario Capo-Chichi, Hubert Tsui, Etienne Mahe, Philip Berardi, Mark D. Minden, Joseph M. Brandwein, Andre C. Schuh
    DOI 10.3390/curroncol30120759 PMID 38132393
    Consulter

  • Molecular targeting of the UDP-glucuronosyltransferase enzymes in high-eukaryotic translation initiation factor 4E refractory/relapsed acute myeloid leukemia patients: a randomized phase II trial of vismodegib, ribavirin with or without decitabine

    Sarit Assouline, Jadwiga Gasiorek , Julie Bergeron , Caroline Lambert, Biljana Culjkovic-Kraljacic, Eftihia Cocolakis, Chadi Zakaria, David Szlachtycz, Karen Yee, Katherine L B Borden
    DOI 10.3324/haematol.2023.282791 PMID 36951168
    Consulter

  • Real-life comparison of posaconazole versus fluconazole for primary antifungal prophylaxis during remission-induction chemotherapy for acute leukemia

    Simon F Dufresne , Julie Bergeron , Stéphanie Beauchemin, Claire Nour Abou Chakra, Barbara Vadnais, Philippe Bouchard, Annie-Claude Labbé, Michel Laverdière
    DOI 10.3138/jammi-2022-0027 PMID 37008582
    Consulter

  • Long-term follow-up of VIALE-C in patients with untreated AML ineligible for intensive chemotherapy

    Andrew H. Wei, Panayiotis Panayiotidis, Pau Montesinos, Kamel Laribi, Vladimir Ivanov, Inho Kim, Jan Novak, Rebecca Champion, Walter Fiedler, Maria Pagoni , Julie Bergeron , Stephen B. Ting, Jing-Zhou Hou, Achilles Anagnostopoulos, Andrew McDonald, Vidhya Murthy, Takahiro Yamauchi, Jianxiang Wang, Qi Jiang, Yan Sun, Brenda Chyla, Wellington Mendes, Courtney D. DiNardo
    DOI 10.1182/blood.2022016963 PMID 36112968
    Consulter

  • Author Correction: 6-month follow-up of VIALE-C demonstrates improved and durable efficacy in patients with untreated AML ineligible for intensive chemotherapy

    Andrew H. Wei, Panayiotis Panayiotidis, Pau Montesinos, Kamel Laribi, Vladimir Ivanov, Inho Kim, Jan Novak, Don A. Stevens, Walter Fiedler, Maria Pagoni , Julie Bergeron , Stephen B. Ting, Jing-Zhou Hou, Achilles Anagnostopoulos, Andrew McDonald, Vidhya Murthy, Takahiro Yamauchi, Jianxiang Wang , Brenda Chyla, Yan Sun, Qi Jiang, Wellington Mendes, John Hayslip, Courtney D. DiNardo
    DOI 10.1038/s41408-021-00565-6 PMID 34702803
    Consulter

  • Pediatric-inspired therapy compared to allografting for Philadelphia chromosome-negative adult ALL in first complete remission

    Matthew D Seftel, Donna Neuberg, Mei-Jie Zhang, Hai-Lin Wang, Karen Kuhn Ballen , Julie Bergeron , Stephen Couban, César O Freytes, Mehdi Hamadani, Mohamed A Kharfan-Dabaja, Hillard M Lazarus, Taiga Nishihori, Kristjan Paulson , Wael Saber, Stephen E Sallan, Robert Soiffer, Martin S Tallman, Ann E Woolfrey, Daniel J DeAngelo, Daniel J Weisdorf; Acute Leukemia Committee of the CIBMTR and the Dana Farber ALL Consortium
    DOI 10.1002/ajh.24285 PMID 26701142
    Consulter

  • A phase I trial of ribavirin and low-dose cytarabine for the treatment of relapsed and refractory acute myeloid leukemia with elevated eIF4E

    Sarit Assouline, Biljana Culjkovic-Kraljacic , Julie Bergeron , Stephen Caplan, Eftihia Cocolakis, Caroline Lambert, Cara J Lau, Hiba Ahmad Zahreddine, Wilson H Miller Jr, Katherine L B Borden
    DOI 10.3324/haematol.2014.111245 PMID 25425688
    Consulter

  • Harnessing the power of alloreactivity without triggering graft-versus-host disease: how non-engrafting alloreactive cellular therapy might change the landscape of acute myeloid leukemia treatment

    Elizabeth F Krakow , Julie Bergeron , Sylvie Lachance , Denis-Claude Roy , Jean-Sébastien Delisle
    DOI 10.1016/j.blre.2014.08.002 PMID 25228333
    Consulter

  • The sonic hedgehog factor GLI1 imparts drug resistance through inducible glucuronidation

    Hiba Ahmad Zahreddine, Biljana Culjkovic-Kraljacic, Sarit Assouline, Patrick Gendron, Andrea A. Romeo, Stephen J. Morris, Gregory Cormack, James B. Jaquith, Leandro Cerchietti, Eftihia Cocolakis, Abdellatif Amri , Julie Bergeron , Brian Leber, Michael W. Becker, Shanshan Pei, Craig T. Jordan, Wilson H. Miller, Katherine L. B. Borden
    DOI 10.1038/nature13283 PMID 24870236
    Consulter

  • Incidence of invasive aspergillosis following remission-induction chemotherapy for acute leukemia: a retrospective cohort study in a single Canadian tertiary care centre

    Sapha Barkati, Simon F. Dufresne, Sylvie Bélanger, Barbara Vadnais , Julie Bergeron , Annie Claude Labbé, Michel Laverdière
    DOI 10.9778/cmajo.20130062 PMID 25077134
    Consulter

  • Extensive molecular mapping of TCRα/δ- and TCRβ-involved chromosomal translocations reveals distinct mechanisms of oncogene activation in T-ALL

    Sandrine Le Noir, Raouf Ben Abdelali, Marc Lelorch , Julie Bergeron , Stephanie Sungalee, Dominique Payet-Bornet, Patrick Villarèse, Arnaud Petit, Céline Callens, Ludovic Lhermitte , Laurence Baranger, Isabelle Radford-Weiss, Marie-José Grégoire, Hervé Dombret, Norbert Ifrah, Salvatore Spicuglia, Serge Romana, Jean Soulier, Bertrand Nadel, Elizabeth Macintyre, Vahid Asnafi
    DOI 10.1182/blood-2012-04-425488 PMID 22948044
    Consulter

  • TLX homeodomain oncogenes mediate T cell maturation arrest in T-ALL via interaction with ETS1 and suppression of TCRα gene expression

    Saïda Dadi, Sandrine Le Noir, Dominique Payet-Bornet, Ludovic Lhermitte, Joaquin Zacarias-Cabeza , Julie Bergeron , Patrick Villarèse, Elodie Vachez, Willem A Dik, Corinne Millien, Isabelle Radford, Els Verhoeyen, François-Loïc Cosset, Arnaud Petit, Norbert Ifrah, Hervé Dombret, Olivier Hermine, Salvatore Spicuglia, Anton W Langerak, Elizabeth A Macintyre , Bertrand Nadel, Pierre Ferrier, Vahid Asnafi
    DOI 10.1016/j.ccr.2012.02.013 PMID 22516263
    Consulter

  • T cell receptor genotyping and HOXA/TLX1 expression define three T lymphoblastic lymphoma subsets which might affect clinical outcome

    Frederic Baleydier, Anne-Valerie Decouvelaere , Julie Bergeron , Philippe Gaulard, Danielle Canioni, Yves Bertrand, Stephane Lepretre, Barbara Petit, Herve Dombret, Kheira Beldjord, Thierry Molina, Vahid Asnafi, Elizabeth Macintyre
    DOI 10.1158/1078-0432.CCR-07-1927 PMID 18245528
    Consulter

  • Prognostic and oncogenic relevance of TLX1/HOX11 expression level in T-ALLs

    Julie Bergeron , Emmanuelle Clappier, Isabelle Radford, Agnès Buzyn, Corinne Millien, Gwendoline Soler, Paola Ballerini, Xavier Thomas, Jean Soulier, Hervé Dombret, Elizabeth A Macintyre, Vahid Asnafi
    DOI 10.1182/blood-2007-04-079988 PMID 17609427
    Consulter

  • HOXA cluster deregulation in T-ALL associated with both a TCRD-HOXA and a CALM-AF10 chromosomal translocation

    Julie Bergeron , E Clappier, B Cauwelier, N Dastugue, C Millien, E Delabesse, K Beldjord, F Speleman, J Soulier, E Macintyre, V Asnafi
    DOI 10.1038/sj.leu.2404187 PMID 16572206
    Consulter

  • T cells targeted against a single minor histocompatibility antigen can cure solid tumors

    Marie-Christine Meunier , Jean-Sébastien Delisle , Julie Bergeron , Vincent Rineau, Chantal Baron, Claude Perreault
    DOI 10.1038/nm1311 PMID 16227989
    Consulter

  • Prevalence of alpha-globin gene deletions among patients with unexplained microcytosis in a North-American population

    Julie Bergeron , Xiaoduan Weng, Louise Robin, Harold J Olney, Denis Soulières
    PMID 15768555
    Consulter

  • A phase II study of topotecan in patients with anaplastic oligodendroglioma or anaplastic mixed oligoastrocytoma

    Karl Bélanger, David MacDonald, Gregory Cairncross, Stan Gertler, Peter Forsyth, Susan Burdette-Radoux , Julie Bergeron , Denis Soulières, Samuel Ludwin, Nancy Wainman, Elizabeth Eisenhauer
    DOI 10.1023/a:1026211620793 PMID 14586216
    Consulter